Telik

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

... permitted after the release of the clinical hold, telik decided not to enroll additional patients, which i...a re-induction platinum-based regimen. About telik Telik, Inc. of Palo Alto, CA, is a clinical sta...n Form 10-Q for the quarter ended March 31, 2009. telik does not undertake any obligation to update forwar...

Telik Announces Preclinical Presentations at AACR Annual Meeting

...its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates. TELIK, the telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc. ...

Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance

...7. For the twelve months ended December 31, 2008, telik reported a net loss of $31.8 million, or $0.60 per...xpenses and legal expenses. In February 2009, telik announced a reorganization to focus resources on i... full data at an upcoming scientific meeting. telik also announced its financial guidance for 2009. T...

Telik Announces Year-End Financial Release, Conference Call and Webcast

...r 612-332-0226. An archive of the conference call will be available on the telik website or by telephone at 800-475-6701 or 320-365-3844, access code 985835...d efficient discovery of small molecule drug candidates. TELIK, the telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of...

Telik Announces Patents on Compounds Related to TELINTRA

...Neutropenia, a common side effect of chemotherapy. telik expects these applications and patents to provide ...market products in the U.S. and foreign countries, telik will not be permitted to commercialize these produ...on Form 10-Q for the quarter ended March 31, 2008. telik does not undertake any obligation to update forwar...

Telik Announces Preclinical Presentations at AACR Annual Meeting

...using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. TELIK, the telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc. ...

Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome

...of cytopenias associated with MDS or chemotherapy. telik has developed both intravenous and Tablet formulat...ve than its product candidates or any product that telik may develop, or obtain marketing approval before T... opportunity will be reduced or eliminated, and if telik does not obtain regulatory approval to market prod...

Telik in Medical Technology

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...al information on TELINTRA is available at www.telik.com . About telik Telik, Inc. of Palo Alto, CA, is a clinical stage drug development ...nd efficient discovery of small molecule drug candidates. TELIK, the telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of...

Telik Announces Presentation at ASCO Annual Meeting

...refractory or resistant ovarian cancer (OC)." About telik Telik, Inc. of Palo Alto, CA, is a clinical stage drug development compa... and efficient discovery of small molecule drug candidates. TELIK, the telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of...

Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

..." in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. telik does not undertake any obligation to update forward-looking statements contained in this press release. TELIK, the telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks o...

Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies

...ced neutropenia, or CIN. As previously reported, telik completed a successful 65 patient Phase 2 study wi...ct candidates, or obtain marketing approval before telik does, Telik's commercial opportunity will be reduced or eliminated, and if telik does not obtain regulatory approval to market prod...

Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting

...nables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com TELIK, the telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc. ...

Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2

... to grow and divide while starving existing tumors of needed blood supply. telik scientists have identified a class of selective small molecule inhibitors o.... Additional information is available at http://www.telik.com TELIK, the telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of...

Telik Announces Telcyta Clinical and Preclinical Presentations at AACR Meeting

...ed December 31, 2006. Telik does not undertake any obligation to update forward-looking statements contained in this press release. NOTE: TELIK, the telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc. CONTACT: Carol D. DeGuzman, Senior Director, Corporate Commu...

Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

...ar ended December 31, 2006. Telik does not undertake any obligation to update forward-looking statements contained in this press release. TELIK, the telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc. CONTACT: Carol D. DeGuzman, Senior Director, Corporate Commu...

Telik in Biological News

Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses

...Genomics Collaborative Inc. Research support from Affymetrix, AmeriPath, the Georgia Cancer Coalition, Agilent Technologies, Amersham Biosciences, and telik Inc. also springboards the effort. Major founding support was provided to IGC from Arizona State University, the City of Phoenix, and from Maricopa...

Telik in Biological Technology

ReceptorBio Announces Diabetes License Agreement With Telik

FOSTER CITY, Calif., Aug. 19 /PRNewswire-FirstCall/ -- ReceptorBio, Inc. announced today that it has entered into a license agreement with Telik, Inc. (Palo Alto, CA) (Nasdaq: TELK ) that would enable ReceptorBio to develop and commercialize Telik's unique, oral small molecule insulin recepto...

Telik Announces Second Quarter 2009 Financial Results

...se. For the six months ended June 30, 2009, telik reported a net loss of $13.4 million, or $0.25 per...sed compensation expense. At June 30, 2009, telik had $50.6 million in cash, cash equivalents and in... $63.5 million at December 31, 2008. About telik Telik, Inc. of Palo Alto, CA, is a clinica...

Telik Reports Preclinical Results at AACR Annual Meeting

... in Denver, CO. The abstracts can be found on the telik website, www.telik.com . In vivo Char...f human cancer. Key findings: telik researchers presented additional data for a novel ...olecular Mechanism of TLK58747; Abstract # 4515 telik researchers identified a novel alkylating agent, T...

Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline

...0, 2008, and other periodic filings with the SEC. The Company does not undertake any obligation to update forward-looking statements. TELIK, the telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc. ...

Telik Announces New TRAP Drug Discovery Agreement

...dhering to and interacting with cellular proteins. telik has developed a novel computational approach to de...orm 10-Q for the quarter ended September 30, 2008. telik does not undertake any obligation to update forwar...ents contained in this press release. TELIK, the telik logo, TELINTRA, TELCYTA, and TRAP are trademarks o...

Telik Announces Financial Results for 2008 Third Quarter

... other income (expense). As of September 30, 2008, telik has recognized impairment charges totaling $6.2 mi...ue auction rate securities. At September 30, 2008, telik had $64.6 million in cash, cash equivalents and in...ny by UBS AG ("UBS"). In October 2008, UBS offered telik the right to sell at par value all of its auction-...

Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer

...uarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release. TELIK, the telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc. ...

Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast

...or 612-332-7517. An archive of the conference call will be available on the telik website or by telephone at 800-475-6701 or 320-365-3844, access code 966597...pid and efficient discovery of small molecule drug candidates. TELIK, the telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of...

Telik Announces Receipt of Nasdaq Notice

...). In accordance with Marketplace Rule 4450(e)(2), telik has 180 calendar days, or until March 18, 2009, to...ays, Nasdaq will provide written notification that telik has achieved compliance. Nasdaq may also require telik to maintain a closing bid price of at least $1.00 ...

Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone

..." in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. telik does not undertake any obligation to update forward-looking statements contained in this press release. TELIK, the telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks o...